Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia

Salvina Maria de Campos-Carli, Aline Silva Miranda, Ingrid Caroline Silva Dias, Amanda de Oliveira, Breno Fiuza Cruz, Érica Leandro Marciano Vieira, Natalia Pessoa Rocha, Izabela Guimarães Barbosa, João Vinícius Salgado, Antônio Lúcio Teixeira

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Objective Changes in immune system have been reported in schizophrenia. This study aimed to evaluate the involvement of IL-33, a member of the IL-1 cytokine family, in schizophrenia and its association with cognitive performance in these patients. Methods Forty patients with chronic schizophrenia and 40 healthy subjects participated in the study. Serum levels of IL-33 and sST2 (soluble form of the IL-33 receptor) were measured using enzyme-linked immunosorbent assay (ELISA). Patients were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Schizophrenia Cognition Rating Scale (SCoRS). Results Patients with schizophrenia and controls presented similar serum levels of IL-33 and sST2. Levels of both markers were positively correlated with cognitive performance in patients with schizophrenia. Conclusion We found a significant correlation between IL-33 and sST2 levels and cognition in schizophrenia. Our results might help in the understanding of how immune markers are associated with cognitive impairment in schizophrenia. It remains to be determined whether the association between IL-33/sST2 and cognition is restricted to patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalComprehensive Psychiatry
Volume74
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia'. Together they form a unique fingerprint.

Cite this